Relative studies have shown that BIIB054 analyzes the efficacy of anti alpha synuclein monoclonal antibody Cinpanemab in reducing injury and disability in Parkinson’s disease patients compared to placebo in the Phase 2 clinical study SPARK. This evidence concerns the gene SNCA and Parkinson disease.